The methodology developed at this point is applicable to other amyloidogenic proteins like tau, Aβ, and TDP-43 and lays the groundwork for precision-engineered therapeutics that counteract protein misfolding in neurodegenerative diseases. This evidence concerns the gene MAPT and neurodegenerative disease.